Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682662 · ClinicalTrials.gov registry record · Phase 4
Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT07682662: Clinical Trial Phase 4 study, sponsored by University of Mississippi Medical Center.
NCT07682662 is a Phase 4 study that has not yet begun recruiting, run by University of Mississippi Medical Center. The registered enrollment target is 400 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07682662, a Phase 4 study, has not yet begun recruiting, sponsored by University of Mississippi Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does Ketamine decrease the amount of time it takes to reach adequate pain control/pain score improvement, as compared to Opioids. Patients could have too low or too high blood pressure or sleepiness. Researchers will compare Ketamine to Opioids (Morphine or Dilaudid) to see if Ketamine works to treat pain enough that you do not need to be admitted to the hospital. Participants will: On arrival to the Children's ER for Sickle Cell Pain crisis will get Ketamine, instead of Morphine or Dilaudid, along with the typical Tylenol, Toradol, Lidocaine patch for pain control while in the ER. During this time we will follow your reported pain scale (0-10) to monitor your pain response to the Ketamine, as well as follow rate of hospital admission.
Interventions
- OTHER Standard Care (in control arm)
- DRUG Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-10-01 |
| Phase | Phase 4 |
What is known before NCT07682662 opens enrollment
NCT07682662 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Care (in control arm) is the first listed.
NCT07682662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07682662 about?
NCT07682662 is a clinical study titled "Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis". The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does K...
What is the current status of trial NCT07682662?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2026-08-01. Estimated completion is 2029-10-01.
What interventions are being tested in trial NCT07682662?
The interventions under investigation include: Standard Care (in control arm) (OTHER), Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses. (DRUG).
Who is sponsoring clinical trial NCT07682662?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07682662's enrollment target sits among peer trials
400 211th of 2000 higher than 1,784 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI